Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02813551 · ClinicalTrials.gov registry record · Phase 2
ToRsemide for pOstpartum HYpertension
A Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT02813551 is a Phase 2 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 118 participants.
The verdict
NCT02813551, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
Currently there is no intervention to prevent persistent postpartum hypertension in preeclamptic women. Physiologically, the use of a pharmacokinetically predictable loop-diuretic is a reasonable intervention to increase elimination of extra fluid accumulated secondary to preeclampsia.The purpose of this study is to assess if Torsemide reduces the incidence of persistent postpartum hypertension in preeclamptic women.
Interventions
- DRUG Placebo
- DRUG Torsemide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2016-08 |
| Est. Completion | 2017-09-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02813551
The ClinicalTrials.gov registry entry for NCT02813551 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02813551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02813551 about?
NCT02813551 is a clinical study titled "ToRsemide for pOstpartum HYpertension". Currently there is no intervention to prevent persistent postpartum hypertension in preeclamptic women. Physiologically, the use of a pharmacokinetically predictable loop-diuretic is a reasonable intervention to increase elimination of extra fluid accumulated secondary to preeclampsia.The purpose of...
What is the current status of trial NCT02813551?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2016-08. Estimated completion is 2017-09-09.
What interventions are being tested in trial NCT02813551?
The interventions under investigation include: Placebo (DRUG), Torsemide (DRUG).
Who is sponsoring clinical trial NCT02813551?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.